5-alpha Reductase Inhibitors
"5-alpha Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
| Descriptor ID |
D058891
|
| MeSH Number(s) |
D27.505.519.389.870.200 D27.505.696.399.450.855.200
|
| Concept/Terms |
5-alpha Reductase Inhibitors- 5-alpha Reductase Inhibitors
- 5 alpha Reductase Inhibitors
- Inhibitors, 5-alpha Reductase
- Reductase Inhibitors, 5-alpha
- Steroid 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Steroid
- Inhibitors, Steroid 5-alpha-Reductase
- Steroid 5 alpha Reductase Inhibitors
- Testosterone 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Testosterone
- Inhibitors, Testosterone 5-alpha-Reductase
- Testosterone 5 alpha Reductase Inhibitors
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitors
- 3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitors
- 4-Dehydrogenase Inhibitors, 3-Oxo-5-alpha-Steroid
- Inhibitors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
|
Below are MeSH descriptors whose meaning is more general than "5-alpha Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "5-alpha Reductase Inhibitors".
This graph shows the total number of publications written about "5-alpha Reductase Inhibitors" by people in this website by year, and whether "5-alpha Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "5-alpha Reductase Inhibitors" by people in Profiles.
-
Halpern EJ, Gomella LG, Forsberg F, McCue PA, Trabulsi EJ. Contrast enhanced transrectal ultrasound for the detection of prostate cancer: a randomized, double-blind trial of dutasteride pretreatment. J Urol. 2012 Nov; 188(5):1739-45.
-
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 01; 118(17):4139-47.
-
Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005 Jan; 65(1):76-82.